Summary: Putting It All Together for 1L EGFRm NSCLC

Misako Nagasaka, MD, closes the program with a 4-part summary of subcutaneous amivantamab every 4 weeks plus lazertinib in the first-line setting for EGFR-mutated advanced non–small cell lung cancer (NSCLC). On efficacy, she revisits the MARIPOSA data: median overall survival not reached vs 36.7 months with osimertinib (HR, 0.75; P = .005), median progression-free survival (PFS) of 23.7 vs 16.6 months (HR, 0.70; P < .001), overall response rates of 86% vs 85%, NCCN Category 1 preferred status, and a higher 36-month on-treatment rate. She reframes these data as supporting an expectation that, with proactive supportive care, most patients can be encouraged to remain on therapy.

On central nervous system (CNS) outcomes, Nagasaka highlights the MARIPOSA brain metastases subgroup: intracranial PFS of 25.4 vs 22.2 months (HR, 0.79), intracranial duration of response of 35.7 vs 29.6 months, and a doubling of the 36-month intracranial PFS rate (36% vs 18%). Protocol-mandated serial MRIs in all participants underpin the reliability of these data, and Category 1 preferred status applies regardless of CNS involvement. On safety and tolerability, she reiterates that only 8% of patients in cohort 5 discontinued all study treatment because of treatment-related adverse events, that the adverse event peak in months 1 through 4 is followed by a predictable decline, and that the COCOON regimen and prophylactic anticoagulation support persistence on therapy. On delivery, she notes the approximately 5-minute administration time, the 80% reduction in administration-related reactions vs the intravenous formulation, and the reduction from 26 to 13 annual visits with dosing every 4 weeks while preserving the MARIPOSA efficacy benchmark.

Thank you for watching this CancerNetwork^® Between the Lines program on subcutaneous amivantamab every 4 weeks plus lazertinib in first-line EGFR-mutated advanced NSCLC. Please subscribe to our e-newsletter for information on upcoming video series.